Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR5109)
Drug Name
Oxycodone
Synonyms .
Indication Pain [ICD11: MG30-MG3Z] Approved [1]
Back pain [ICD11: ICD11: ME84] Phase 3 [2]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 315.4 Topological Polar Surface Area 59
Heavy Atom Count 23 Rotatable Bond Count 1
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 5
Cross-matching ID
PubChem CID
5284603
ChEBI ID
CHEBI:7852
CAS Number
76-42-6
TTD Drug ID
D03SKD
Formula
C18H21NO4
Canonical SMILES
CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O
InChI
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
InChIKey
BRUQQQPBMZOVGD-XFKAJCMBSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
(Alpha and beta)-Oxycodol DM016577
129856110
Unclear - Unclear 1 [6]
Noroxycodone DM001122
5489120
Unclear - Unclear 1 [6]
Oxycodone N-oxide DM016320
71623259
Unclear - Unclear 1 [6]
Zanubrutinib Metabolite M5 DM003074
5284604
Unclear - Unclear 1 [6]
Zanubrutinib Metabolite M2 DM001121
5497189
Unclear - Unclear 2 [6]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR013818 Oxycodone Noroxycodone Unclear - Unclear CYP3A4 [6]
MR013820 Oxycodone Oxymorphone Unclear - Unclear CYP2D6 [6]
MR013822 Oxycodone (Alpha and beta)-Oxycodol Unclear - Unclear Unclear [6]
MR013823 Oxycodone Oxycodone N-oxide Unclear - Unclear FMO3 [6]
MR013819 Noroxycodone Noroxymorphone Unclear - Unclear CYP2D6 [6]
MR013821 Oxymorphone Noroxymorphone Unclear - Unclear CYP3A4 [6]
⏷ Show the Full List of 6 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
Cytochrome P450 3A4 (CYP3A4) DME0001 Homo sapiens
CP3A4_HUMAN
1.14.14.55
[3]
Cytochrome P450 3A5 (CYP3A5) DME0012 Homo sapiens
CP3A5_HUMAN
1.14.14.1
[4]
UDP-glucuronyltransferase (UGT) DMEN064 . Not Available Not Available [5]
References
1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7093).
2 ClinicalTrials.gov (NCT01427283) A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain. U.S. National Institutes of Health.
3 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
4 CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone
5 Characterization of oxycodone in vitro metabolism by human cytochromes P450 and UDP-glucuronosyltransferases
6 Metabolism and Disposition of Prescription Opioids: A Review

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.